Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections

Study Overview
=================
Brief Summary
-----------------
the aim of this study is to investigate the relationship between exposure to daptomycin and the occurrence of muscle toxicity or eosinophilic pneumonia in patients treated with daptomycin for bone and joint infection

Detailed Description
-----------------
Daptomycin is widely used in osteoarticular infections (IOA), as an alternative to vancomycin, and recommended for this use by various learned societies including the Infectious Diseases Society of America (IDSA) in 2013. Tolerance to daptomycin is generally favorable, with in particular better renal tolerance than vancomycin. However, two rare and potentially severe side effects have been described with this antibiotics: muscle toxicity and eosinophilic pneumonia.

Official Title
-----------------
Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections

Conditions
-----------------
Dactinomycin Adverse Reaction, Bone and Joint Infection

Intervention / Treatment
-----------------
* Other: patients having had BJI or PJI treated with daptomycin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have had an osteoarticular infection, treated with daptomycin, with at least one blood test for daptomycin performed Exclusion Criteria: Patients who objected to participating in the study Absence of blood dosage of daptomycin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients having had BJI or PJI treated with daptomycin<br>patients having an osteoarticular infection treated with daptomycin and which developped eosinophilic pneumonia or elevation of CPK | Other: patients having had BJI or PJI treated with daptomycin<br>* patients having had BJI or PJI treated with daptomycin who developped an adverse event : eosinophilic pneumonia and/or elevation of CPK<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of patients having had a PJI or BJI treated by daptomycin | proportion of patients treated by daptomycin | between 2010 and 2020 | 
| description of BJI/PJI | type of BJI or PJI | between 2010 and 2020 | 
| description of patients | comorbidites | between 2010 and 2020 | 
| description of adverse event | type of adverse event | between 2010 and 2020 | 
| rate of patients having had an adverse event | proportion of patients having had an adverse event under daptomycin | between 2010 and 2020 | 
| Evalutation of the adverse event due to daptomycin : dosage of daptomycine | description of the use of daptomycine : dosage | between 2010 and 2020 | 
| Evalutation of the adverse event due to daptomycin : duration of daptomycine | description of the use of daptomycine : duration | between 2010 and 2020 | 
| Evalutation of the adverse event due to daptomycin : daptomycine plasma clearance | mean daptomycine plasma clearance (unit, liters per hour) | between 2010 and 2020 | 
| Evalutation of the adverse event due to daptomycin : daptomycine volume distribution | mean daptomycine volume of distribution (unit, liters) | between 2010 and 2020 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CPK, bone and joint infection, adverse event, daptomycin, Eosinophilic pneumonia, rhabdomyolysis